Agoracom Blog

KWESST $KWE.ca $KWEMF Establishes ATAK Centre of Excellence in Ottawa $WRTC $BYRN.ca $PAT.ca $POWW

Posted by AGORACOM-JC at 8:02 AM on Tuesday, March 30th, 2021

Incremental, near-term recurring revenue stream from support services

  • Announced that it has established an ATAK Centre of Excellence in Ottawa.
  • The centre will facilitate customer requirements for integration into the U.S. battlefield management application known as ATAK (Android Tactical Assault Kit).

Ottawa, Ontario–(March 30, 2021) – KWESST Micro Systems Inc. (TSXV: KWE) (OTCQB: KWEMF) (“KWESST” or “the Company”) today announced that it has established an ATAK Centre of Excellence in Ottawa. The centre will facilitate customer requirements for integration into the U.S. battlefield management application known as ATAK (Android Tactical Assault Kit).

ATAK is an Android geospatial and situational awareness system that provides users with a drop-down menu of approved operational applications for shared situational awareness. It is the pre-eminent system used by more than a dozen U.S. government agencies and many NATO allies and partner nations.

As mentioned in the Company’s announcement of March 16th, 2021, KWESST was officially sponsored by U.S. military authorities to integrate certain of the Company’s networked soldier applications into ATAK. In conjunction, the U.S. military provided KWESST with specialized software necessary for this work.

“Since then, we have received many requests from government agencies and defence contractors in Canada and overseas to assist them with integrating their current or new applications into ATAK and providing through-life support,” said Jeff MacLeod, KWESST President and CEO. He added that, “We are already engaged with a number of customers and have many others in the queue. As a result we are ramping up a dedicated practice for this and leveraging our expertise in ATAK integration.”

The Company stated that its ATAK Centre of Excellence is a natural extension of its core business around digitizing applications “at the tactical edge” for shared situational awareness and targeting. KWESST’s other applications include its TASCS system and its related Integrated Fires Module (IFM) application, currently being delivered to a major U.S. military customer.

“Apart from the revenue potential, this further positions KWESST as a leader in the digitization of land forces at the tactical level, pushing critical information and high-value applications to the individual soldier on the ground and back up through the chain of command,” said MacLeod. “This continues to be a key missing link in the modernization of soldier systems.”

The Company added that digitization of land forces at the tactical level is happening now and happening everywhere. One market study(1) projects it to be worth more than $15B CAD by 2024. “To our knowledge, KWESST is the only Canadian company with the credentials, official U.S. military sponsorship, specialized software and the experience to facilitate ATAK integration,” said MacLeod.

The Company stated that its ATAK Centre of Excellence can assist government and industry clients with end-to-end ATAK application development, facilitate approval with U.S. ATAK authorities, and provide ongoing support. “We believe that this can contribute incrementally to our 2021 revenue plan, with recurring support revenue growth in out-years,” concluded MacLeod.

(1) https://www.marketsandmarkets.com/Market-Reports/soldier-system-market-137230260.html

Read More: https://agoracom.com/ir/Kwesst/forums/discussion/topics/758213-kwesst-establishes-atak-centre-of-excellence-in-ottawa/messages/2310248#message

AGORACOM Small Cap 60: Fabled Silver Gold’s Big Picture $FCO.ca $FBSGF $RDU.ca $KTN.ca $GMBXF $EDR.ca

Posted by AGORACOM at 2:48 AM on Tuesday, March 30th, 2021
This image has an empty alt attribute; its file name is fabled-square.png

AGORACOM Small Cap 60: Candente Copper $DNT.ca 9 Billion Pounds Copper, 2 Million Ounces Gold, 54 Million Ounces Silver $FCX.ca $TECK.ca $FSUGY $PER.ca

Posted by AGORACOM at 1:28 AM on Tuesday, March 30th, 2021
http://blog.agoracom.com/wp-content/uploads/2020/08/candente-copper-for-blog1.jpg

VIDEO – Valeo Pharma $VPH $VPHIF Enters Commercialization and Supply Agreement With Novartis To Address the $700M/ Year CDN Asthma Medication Market $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 5:41 PM on Monday, March 29th, 2021

Valeo Pharma Inc . (VPH: CSE) (VPHIF: OTCQB) (VP2: FSE) announced today that it has entered into a Commercialization and Supply Agreement with Novartis Pharmaceuticals Canada Inc.for the Canadian commercialization by Valeo of two asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate),  glycopyrronium (as bromide) and mometasone furoate) 3 and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate).

Under the Agreement, Valeo will be responsible for medical and commercial activities for an initial 8 year period.

How Significant Is This Market?

At present, almost 4 million Canadians are living with asthma a serious health issue affecting all age groups. Patients with severe asthma live in fear of potential exacerbations which remain highly prevalent even with today’s most advanced therapies. The Canadian market for asthma medication exceeds $700M annually.

What Does The CEO of Valeo say about the deal?

“We are extremely pleased to be partnering with Novartis to launch these two  asthma drugs in the coming weeks. Commercializing Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® will immediately position Valeo as one of the leading Canadian respiratory companies providing first in-class and best in-class asthma therapies. The Canadian asthma maintenance market exceeds $700M annually,” said Steve Saviuk , CEO of Valeo. “This partnership is perfectly aligned with Valeo’s vision and mission of building a Canadian anchor pharmaceutical company by driving therapeutic innovation to patients in need. We look forward to building a long and mutually beneficial relationship with Novartis that will help both companies fulfill their respective missions.”

Sit Back, relax and watch this powerful interview with Steve Saviuk , CEO of Valeo.

AGORACOM Small Cap 60: Liquid Avatar $LQID CEO Feeling Euphoric By Involvement In NFT/ Rock and Roll History $MOS.ca $MOGO.ca $CTZ.ca

Posted by AGORACOM-JC at 5:24 PM on Monday, March 29th, 2021

VIDEO – From Rockets to MRIs: Royal Helium $RHC.ca Plans to Discover and Provide A Multi-Use Gas in Short Supply $DME.ca $APD $AHELF

Posted by AGORACOM-JC at 4:14 PM on Monday, March 29th, 2021

If you think about balloons / blimps when thinking about Helium uses, we wouldn’t blame you … but you’d also be missing out on a much much bigger picture.

Looking beyond just balloons, Helium is a high tech gas, with many uses in rocket engines, semiconductors, electronics, and health care. These sectors pressure the demand for helium in concert, making it a gas in very short supply.  Prices have been rising due to a shortage in supply.

Saskatchewan is one of the only places on earth with current and past production of primary Helium. This is where Royal  Helium comes into play as they are one of the largest land holders searching for Helium and have already drilled 3 holes at their Climax project.  

Worldwide usable Helium is in short supply as demand is increasing, making it a high-priced commodity, take a seat and discover why Royal Helium is the next SmallCap Stock to discover.

AGORACOM Small Cap 60: PK Beans $BEAN On The Company’s Success Building a Leading Children’s Lifestyle Brand $LULU

Posted by AGORACOM-JC at 4:03 PM on Monday, March 29th, 2021

Valeo Pharma $VPH $VPHIF Enters into an Agreement for Enerzair® Breezhaler® and Atectura® Breezhaler® in Canada $HLS.ca $MDP.ca $GUD.ca $RX.ca

Posted by AGORACOM-JC at 10:47 AM on Monday, March 29th, 2021
Valeo Pharma (@valeo_pharma) | Twitter
  • Valeo to commercialize Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® , 2 innovative asthma therapies approved by Health Canada
  • Positions Valeo as one of the leading Canadian Respiratory companies
  • Almost 4 million Canadians afflicted with asthma 1 ; Canadian market for asthma medication exceeds $700M annually 2

MONTREAL , March 29, 2021 – Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (” Valeo ” or the ” Company “), a Canadian pharmaceutical company, announced today that it has entered into a Commercialization and Supply Agreement (the ” Agreement “) with Novartis Pharmaceuticals Canada Inc. (” Novartis “) for the Canadian commercialization by Valeo of two asthma therapies, Enerzair ® Breezhaler ® (indacaterol (as acetate),  glycopyrronium (as bromide) and mometasone furoate) 3 and Atectura ® Breezhaler ® (indacaterol (as acetate) and mometasone furoate) 4 .

Under the Agreement, Valeo will be responsible for medical and commercial activities for Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® for an initial 8 year period.

At present, almost 4 million Canadians are living with asthma 1 , a serious health issue affecting all age groups. Patients with severe asthma live in fear of potential exacerbations which remain highly prevalent even with today’s most advanced therapies . Asthma related exacerbations are concerning because of their associated mortality burden and also because of the increased risk of side effects from the use of systemic corticosteroids. Furthermore, there is growing evidence highlighting the lack of symptom control currently achieved in asthma. 39% 5 of patients remain uncontrolled, despite available dual LABA/ICS medications, primarily due to low adherence, treatment misuse and poor inhaler technique. There is an urgent need to add effective maintenance treatment options to  more efficiently address  symptoms as well as asthma related long-term complications and mortality.

“We are extremely pleased to be partnering with Novartis to launch these two  asthma drugs in the coming weeks. Commercializing Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® will immediately position Valeo as one of the leading Canadian respiratory companies providing first in-class and best in-class asthma therapies. The Canadian asthma maintenance market exceeds $700M annually,” said Steve Saviuk , CEO of Valeo. “This partnership is perfectly aligned with Valeo’s vision and mission of building a Canadian anchor pharmaceutical company by driving therapeutic innovation to patients in need. We look forward to building a long and mutually beneficial relationship with Novartis that will help both companies fulfill their respective missions.”

“This agreement with Valeo Pharma  fits with  our overall strategy to provide innovative medicines that have the potential to improve health outcomes,” said Andrea Marazzi , Head, Country Pharma Organization, Novartis Pharmaceuticals Canada Inc. “Valeo’s commitment and focus to bring Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® to Canadians, combined with our strong respiratory experience, brings  a solution that will help make asthma control a more attainable goal for some Canadians.”

Commenting on this commercial agreement with Novartis, Frederic Fasano , Valeo’s recently appointed President and COO said, “Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® are both benefitting from an extensive phase III clinical trial program including more than 7,500 asthma patients. The efficacy of both treatments on symptoms, lung function and rate of exacerbations have been demonstrated and this will provide Canadian patients with a significant improvement over current standards of care.” He added, “This significant addition to our expanding product portfolio is key to achieving our growth objectives. It will provide the basis for the upscaling of our organization and set the stage for future international expansion.”

The Enerzair ® Breezhaler ® and Atectura ® Breezhaler ® will both be available in the hydrofluoroalkane/chlorofluorocarbon (HFA/CFC)-free Breezhaler ® device.

Atectura, Enerzair and Breezhaler are registered trademarks.

Source: https://agoracom.com/ir/ValeoPharma/forums/discussion/topics/758170-valeo-pharma-inc-enters-into-an-agreement-for-enerzair-breezhaler-and-atectura-breezhaler-in-canada/messages/2310143#message

Predictmedix Inc. $PMED.ca $PMEDF Announces Engagement of Investment Banking Firm Kingswood Capital Markets $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM at 10:14 AM on Monday, March 29th, 2021
PMED PredictMedix

TORONTO, March 29, 2021 (GLOBE NEWSWIRE) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”), a leader in providing AI-powered healthcare solutions is pleased to announce that it has appointed Kingswood Capital Markets (“Kingswood”) in preparation to become a NASDAQ-listed company.

The acceptance of the application to list the Company’s common shares on NASDAQ will be subject to a number of regulatory and listing requirements, including without limitation: retaining the required number of market makers for the Company’s common shares; the filing of the applicable registration statement with the U.S. Securities and Exchange Commission to become a reporting company under the U.S. Securities Act; and the review of the Company and acceptance for listing by NASDAQ. There can be no assurance that NASDAQ acceptance will be granted should the Company submit its listing application.

Kingswood Capital Markets is a global full-service middle market investment bank. Kingswood helps its clients grow through optimal capital raising structures. Its team of experienced investment professionals has collectively financed over $50 billion in public and private capital markets and provides strategic solutions to clients across a wide spectrum of industries.

Kingswood’s expertise has been engaged to aid in both Predictmedix’s NASDAQ uplist and business growth, as part of the Company’s endeavors to disrupt the current healthcare and technology market in a safe, non-invasive, and economically sustainable way.

Read More: https://agoracom.com/ir/Predictmedix/forums/discussion/topics/758166-predictmedix-inc-announces-engagement-of-investment-banking-firm-kingswood-capital-markets/messages/2310138#message

Immersive Tech, a Victory Square Technologies $VST.ca $VSQTF Portfolio Company, Announces C$1.5 Million Non-Brokered Private Placement $YDX.ca $NTAR.ca $SEV.ca $DBO.ca

Posted by AGORACOM at 10:01 AM on Monday, March 29th, 2021
Victory Square Technologies VST

VANCOUVER, British Columbia, March 29, 2021 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square”) (CSE:VST) (OTC:VSQTF) (FWB:6F6) is pleased to announce that its portfolio company Fantasy 360 Technologies Inc. d/b/a Immersive Tech (“Immersive”) has launched a non-brokered private placement of up to 4,285,714 subscription receipts of Immersive (“Subscription Receipts”) at a price of CAD$0.35 per Subscription Receipt for aggregate gross proceeds of up to CAD$1,500,000 (the “SR Offering”).

The Subscription Receipts will be issued pursuant to and governed by a subscription receipt agreement to be entered between Immersive and an escrow agent to be appointed by Immersive on or prior to the closing date of the SR Offering (the “SR Agreement”). The proceeds of the SR Offering, minus 10% which will be immediately released to Immersive on closing of the SR Offering for the purposes of satisfying the Escrow Release Conditions (as defined below) and for working capital and general corporate purposes, will be deposited in escrow pursuant to the SR Agreement.

In accordance with the SR Agreement, each Subscription Receipt shall be automatically converted without any further action on the part of the holder thereof into one unit of Immersive (each, a “SR Unit”) upon the satisfaction of certain escrow release conditions (the “Escrow Release Conditions”) including the receipt of conditional approval by Immersive with respect to the listing of the common shares of Immersive (“Immersive Shares”) on the Canadian Securities Exchange (the “CSE”) and the receipt of a final prospectus of Immersive in the Province of British Columbia. If the Escrow Release Conditions are not satisfied by August 31, 2021, the proceeds of the SR Offering will be returned to the subscribers.

Each SR Unit will consist of one Immersive Share and one-half of one Immersive Share purchase warrant (each whole warrant, an “SR Warrant”). Each SR Warrant will entitle the holder thereof to purchase one additional Immersive Share at a price of CAD$0.52 for a period of 24 months following the completion of a going-public transaction by Immersive.

Read More: https://agoracom.com/ir/VictorySquareTechnologies/forums/discussion/topics/758163-immersive-tech-a-victory-square-technologies-portfolio-company-announces-c-1-5-million-non-brokered-private-placement/messages/2310135#message